Clinical Trials Browser

Triple Negative Breast Neoplasms × tocilizumab × 90 days × Clear all

NCT05846789 2026-05-08

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms